[{"id":"706663a7-a978-4e9d-b057-4930c92e0793","acronym":"","url":"https://clinicaltrials.gov/study/NCT05642195","created_at":"2022-12-08T15:58:15.185Z","updated_at":"2025-02-25T12:29:14.210Z","phase":"Phase 1/2","brief_title":"Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05642195","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anktiva (nogapendekin alfa inbakicept-pmln) • H1299 lung cancer cell lysate vaccine with Montanide ISA-51 VG adjuvant"],"overall_status":"Suspended","enrollment":" Enrollment 30","initiation":"Initiation: 02/27/2025","start_date":" 02/27/2025","primary_txt":" Primary completion: 12/30/2033","primary_completion_date":" 12/30/2033","study_txt":" Completion: 12/30/2035","study_completion_date":" 12/30/2035","last_update_posted":"2025-02-24"}]